The outlook of companies tied to flagship drugs like Viagra presents a nuanced investment picture. While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the loss of exclusivity in key territories has introduced substantial uncertainty . Investors are now grappling with the impact of lower-c